Evasion of cell death by overexpression of anti-apoptotic proteins, such as Bcl-2, is commonly observed in cancer cells leading to a lack of response to chemotherapy.
Introduction
Chemotherapy remains a fundamental part in the treatment of cancer.
Chemoresistance of cancer cells, however, continues to be a major problem [1] .
Current anti-cancer treatments kill tumor cells by inducing apoptosis or other forms of programmed cell death [2] . Apoptosis can be triggered either at the cell surface (extrinsic pathway) or at the mitochondria (intrinsic pathway) [2] . Many standard chemotherapeutics act via mitochondria, inducing cytochrome c release into the cytosol , which results in the assembly of the apoptosome and the activation of caspase-9, initiating a caspase cascade leading to apoptotic cell death. In contrast, when AIF (apoptosis-inducing factor), Omi/HtrA2 (high-temperature-requirement protein A2) or endonuclease G are released into the cytosol, a caspase-independent cell death can occur [3] .
Members of the Bcl-2 (B-cell lymphoma) family are important regulators of the intrinsic pathway of apoptosis [4, 5] . They control mitochondrial outer membrane permeability promoting or inhibiting the release of mitochondrial proteins. Bcl-2, the first member of this family discovered, protects cells from apoptosis by inhibiting oligomerisation and pore formation induced by the pro-apoptotic Bcl-2 family members Bax and Bak or by sequestering pro-apoptotic BH3-only proteins. Since overexpression of Bcl-2 often confers chemoresistance, Bcl-2 is a promising therapeutic target [1, 6, 7] . Bcl-2 is also localized at membranes of the endoplasmic reticulum (ER) where it regulates Ca 2+ homeostasis by desensitizing cells to stimuli that cause the release of ER-sequestered Ca 2+ [8, 9] . Autophagy is another strongly regulated cellular program, in which's regulation Bcl-2 is involved [10] . Autophagy has been interpreted as a form of non-apoptotic death as well as a survival strategy during stress [11] . Recently, a link between Bcl-2 and constitutive activation of nuclear factor B (NF-B) [12] [13] [14] [15] , another crucial player for cell survival and apoptosis resistance in cancer [16] , has been described.
We could previously show that the sesquiterpene lactone helenalin, a secondary plant metabolite, induces apoptosis in Jurkat leukemia cells, which was caspase dependent and moreover cell death in Jurkat cells overexpressing Bcl-2 [17] .
Obviously, helenalin is able to overcome Bcl-2-mediated chemoresistance, however the mechanism is still unknown. Aim of this study, therefore, was to characterize the mechanism of cell death induced by helenalin in Bcl-2 overexpressing cancer cells.
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The clonogenic assay was carried out as previously described [20] and colonies were scored after 7 days of culture using the analysis system from S.CO LifeScience (Garching, Germany). The clonogenic assay with Neo L3.6pl and Bcl-2 L3.6pl cells was performed as previously described [18] . Cells were stained with crystal violet (0.5% crystal violet in 20% methanol) and quantified by absorption measurement (550 nm; SpectraFluor Plus TM (Tecan; Männedorf, Austria)).
Apaf-1 and AIF siRNA
Sense and antisense siRNA oligonucleotides corresponding to nucleotides 978-998
of Apaf-1 [21] (AATTGGTGCACTTTTACGTGA), to the AIF nucleotides [22] (GGAAATATGGGAAAGA-TCCdTdT) and oligonucleotides corresponding to a scramble sequence were purchased from Biomers.net GmbH (Ulm, Germany). Bcl-2
Jurkat cells were transfected with 3 µg of scramble, Apaf-1 or AIF siRNAs using the Amaxa ® Cell Line Nucleofector Kit ® V (LONZA Cologne AG, Cologne, Germany).
Cells were treated 48 h after transfection.
Measurement of cytochrome c release
Release of cytochrome c from mitochondria was analyzed as previously described [17] . Purity of cytosolic fractions was assessed by incubating membranes with VDAC antibody (Cell signalling, Frankfurt, Germany)
Western blot analysis
Samples were treated as described before [20] and membranes were incubated overnight at 4°C with the following specific antibodies: Apaf-1 (BD Transduction Laboratories, Heidelberg, Germany), Bcl-2, eIF2α (D-3), caspase-3 (Santa Cruz Biotechnology, Heidelberg, Germany), cytochrome c, JNK, pJNK (Thr183/Tyr185), VDAC, AKT, mTOR, Beclin-1, LC3B (G40), p-c-Jun (Ser63) II, p-eIF2α (Ser 51), caspase-9, pAKT (Ser473), p-mTOR (Ser2448) (Cell Signaling, Frankfurt, Germany), ANTI-GADD153/CHOP10 (Sigma, Saint Louis, Missouri, USA), BiP/GRP78 (BD Transduction Laboratories, Heidelberg, Germany). Equal protein loading was controlled by β-actin (Millipore, Billerica, MA, USA) staining of membranes. 
Measurement of ROS generation

Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared and EMSA was carried out using P
32
-labeled NF-B consensus sequence oligonucleotides (Promega, Heidelberg, Germany) as previously described [23] . Gels were exposed to Cyclone Storage Phosphor Screens (Canberra-Packard, Schwadorf, Austria) followed by analysis with a phosphor imager station (Cyclone Storage Phosphor System, Canberra-Packard). The composition of p65/p50 of NF-B was confirmed by supershift analysis using antibodies against p65 and p50, respectively [24] .
Measurement of mitochondrial potential
The measurement was performed as previously described [17] . Cells were stained with 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazol-carbocyanine iodide (JC-1) (Axxora, Lörrach, Germany) at a final concentration of 1.25 µM for 15 min at 37°C
and analyzed by flow cytometry.
Caspase activity assay
Caspase activity was determined as described before [17] . Caspase substrates: Ac-LETD-AFC for caspase-8 or Ac-DEVD-AFC (Bachem, Bubendorf, Germany) for caspase-3, respectively. Caspase activity was monitored by a plate-reading 7 multifunction photometer (SpectraFluor PlusTM, Tecan, Männedorf, Austria) after 2 h at 37°C.
Transmission Electron Microscopy (TEM)
Jurkat and Bcl-2 Jurkat cells were left untreated (Co) or treated with helenalin for 8 hours and TEM was carried out as described before [25] .
Statistical analysis
All experiments were performed at least three times. 
Helenalin does not abrogate mitochondrial function of Bcl-2 and acts independently of mitochondria and the apoptosome
Next, we focused on the mechanism leading to cell death in Bcl-2 overexpressing Jurkat cells. Helenalin did not alter Bcl-2 protein level, nor did it induce Bcl-2 phosphorylation as seen after paclitaxel treatment (Fig. 2a) . Moreover, helenalin does not abrogate the function of Bcl-2 on mitochondria since the mitochondrial membrane potential was kept nearly intact and only minute amounts of cytochrome c were released into the cytosol in Bcl-2 overexpressing compared to vector control (Neo Jurkat) cells treated with helenalin ( Fig. 2b-c ).
To underline these findings, transmission electron microscopy (TEM) was performed.
In wild-type Jurkat cells exposed to 20 µM helenalin mitochondria showed severe ultrastructural changes: all stages of desintegration were observed starting from swelling of the cristae and compaction of the matrix, up to mitochondrial "ghosts" with only residual inner membrane and cristae visible (Fig. 3 , upper part). These structural findings concur with biochemical data: In wild-type Jurkat cells, loss of mitochondrial membrane potential, cytochrome c release and caspase activation was observed in response to helenalin [17] . In contrast, in Bcl-2 overexpressing Jurkat cells exposed to 20 µM helenalin mitochondria remain structurally more or less uninfluenced (Fig. 3, lower part) which is in accordance with a lack of cytochrome c release and an intact M a n u s c r i p t mitochondrial membrane potential ( Fig. 2b-c) . Notably, the intermembrane space of the nuclear envelope drastically swells and numerous vesicles form in the cytoplasm in helenalin treated Bcl-2 overexpressing cells.
Silencing of Apaf-1 via siRNA did not influence the induction of cell death by helenalin (Fig. 4a ). This fact further suggests that helenalin-induced cell death occurs independently of the apoptosome and mitochondria. Accordingly, caspase activity measurements ( Fig 
Potential mechanisms used by helenalin to bypass Bcl-2-mediated cytoprotection
We analyzed potential non-apoptotic events leading to helenalin-mediated cell death, such as autophagy and ER-stress. ER-stress induction has recently been linked to induction of autophagy [11, 27] . Helenalin did not affect the expression of BiP/GRP78
and CHOP/GADD153, two critical UPR-upregulated proteins during ER-stress ( Fig.   5a ). Furthermore, increased Ca 2+ -levels, as seen after treatment with thapsigargin, an inhibitor of the endoplasmatic reticulum Ca 2+ ATPase (SERCA), was not observed after stimulation with helenalin (supplement fig. 3a ,b). However, a strong transient activation of JNK, a rapid phosphorylation of eIF2α and a slightly reduced phosphorylation of mTOR in Bcl-2 overexpressing cells was detected upon helenalin treatment ( Fig. 5b and supplement fig. 3b ,c). All three events have been linked to induction of autophagy [11, 27] . Nevetheless, no accumulation of LC3 II, commonly observed during autophagy, could be detected by Western blot analysis (Fig. 5c ), 10 and 3-MA, a well established inhibitor of autophagy [28] , partly diminished helenalininduced cell death after 16 h stimulation but not after 48 h (Fig. 5d) . Furthermore TEM analysis of helenalin treated cells did not reveal significant occurrence of autophagolysosomes (Fig. 3) .
We then examined mediators involved in signaling events of programmed necrosis.
Necrostatin-1 (Nec-1) inhibits RIP1 and acts as a specific inhibitor of necroptotic cell death [29] . Exposure of Bcl-2 Jurkat cells to Nec-1 prior to helenalin treatment did not prevent cell death (Fig. 5e ), arguing against necroptosis as a mode of cell death induced by helenalin. In contrast, Nec-1 abrogated necroptosis induced by TNF-α in the presence of cycloheximide and the pan-caspase inhibitor Q-VD-OPh in Jurkat cells (positive control) [30] (Fig. 5e insert) . An early JNK activation as observed in response to helenalin has been associated with programmed necrosis [29] . Yet, JNK activation by helenalin does not contribute to cell death as indicated by the use of SP600125, a commonly used JNK inhibitor (activity was confirmed by analyzing the phosphorylation of the JNK downstream target c-Jun) ( Fig. 5f and insert).
In addition, helenalin reduced Akt activation (supplement fig. 3d ), which is an important survival factor in cancer cells [31] . However, in Bcl-2 overexpressing cells reduction of Akt activity does not seem to be involved in cell death as wortmannin, a potent inhibitor of Akt phosphorylation, does neither induce cell death itself nor adds to the toxicity of helenalin in Bcl-2 overexpressing Jurkat cells (supplement fig. 3e ).
Role of NF-κB
Since a link of Bcl-2 and the NF-κB signaling pathway has been described for other cell lines [12] [13] [14] [15] 32] , we examined 1) whether Bcl-2 overexpressing Jurkat cells
show increased NF-κB activity and if so, 2) whether helenalin is able to interfere with it. As shown in Fig. 6a , NF-κB-dependent gene transactivation as well as DNA binding activity were increased in Bcl-2 overexpressing Jurkat cells. NF-κB is known to be an important mediator of survival and death resistance in leukemia cells [33] .
Helenalin significantly reduced NF-κB-dependent gene transactivation and DNA binding activity in Bcl-2 overexpressing cells (Fig. 6b) . In addition, also the NF-κB inhibitor BMS-345541, acting on the IκB kinase complex, induced cell death in Bcl-2-protected cells (supplement fig. 4a ) pointing to NF-κB as an attractive target against Bcl-2-conferred cell death resistance. In search of a potential mechanism downstream of NF-κB we measured intracellular ROS level. Helenalin (20 µM) increased intracellular ROS level comparable to H 2 O 2 (17, 6 µM), which was used as a positive control (Fig. 7a ). An antioxidant such as NAC completely prevented and the radical scavenger Tiron attenuated cell death induced by helenalin in Bcl-2 overexpressing Jurkat cells indicating that the Bcl-2 resistance overcoming mechanism of helenalin requires ROS production (Fig. 7b) . Moreover, helenalininduced cell death involves iron ions since the use of the iron chelator desferrioxamine (DFO) inhibits cell death induction by helenalin (Fig. 7c) . Thus, ROS production by helenalin might partly depend on the Fenton reaction as reported by others [33] . Since BMS induced inhibition of NF-B only partly abrogated ROS response by helenalin (supplement fig. 4b ) ROS induction by helenalin seems to occur both upstream as well as downstream of NF-B.
Discussion
The present paper highlights helenalin as a small molecule that is able to overcome Bcl-2-mediated chemoresistance in tumor cells. The major mechanisms that mediate this important feature are 1) the inhibition of Bcl-2-induced upregulation of NF-κB activity and 2) the generation of reactive oxygen species.
Sesquiterpene lactones (STL) such as helenalin comprise a large group of secondary plant metabolites with various biological activities that are linked to the high reactivity of their α,β-unsaturated carbonyl structures with thiol groups by a Michael-type reaction [34] . Interestingly, helenalin has recently gained considerable attention as a lead structure for the treatment of inflammation [35, 36] , whereas the related STL parthenolide has been preferentially appreciated as experimental tumor drug [37] [38] [39] .
However, our work and several other groups attribute an in vitro as well as in vivo antitumor activity also to helenalin [17, [40] [41] [42] . Both compounds have been shown to interfere with the signal transduction of NF-κB [35, 43] playing a pivotal role both in inflammation and cancer [44, 45] . One of the most documented functions of NF-κB in cancer is its ability to promote cell survival by the induction of target gene products that inhibit the apoptotic machinery in both normal and malignant cells [46] . However, NF-κB can also prevent programmed necrosis by inducing genes that encode antioxidant proteins [47] . Thus, helenalin-induced ROS production in conjugation M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 with an impaired antioxidative defense of helenalin-treated tumor might account for its success.
Interestingly, in most cases NF-κB is activated in malignant cells in response to inflammatory stimuli originating from the microenvironment [16] . In addition, intrinsic mutations of the upstream regulators of NF-κB such as receptor activator of NF-κB (RANK), Notch1 or CD40 activity are discussed. Importantly, especially with respect to our work, a link between Bcl-2 and constitutive activation of NF-κB has been described in embryonic kidney cells as well as in myocytes [12, 13] . Moreover, downregulation of Bcl-2 was shown to attenuate NF-κB activation [13] . However, others report that Bcl-2 inhibits NF-κB activity and subsequently apoptosis in serumdeprived embryonic kidney cells [14] .
In this study we show that Bcl-2 overexpressing Jurkat T cells have increased NF-κB activity compared to empty vector control cells. These data are supported by several other observations: 1) lymphoma cells with the t(14;18) translocation show high levels of NF-κB [15] and 2) in breast cancer and leukemic (CLL) cells high NF-κB expression was associated with high Bcl-2 expression [48] . In fact, it has been shown for MCF-7 breast cancer cells that Bcl-2 overexpression enhances NF-κB activity and induces MMP-9 transcription [32] . Thus Bcl-2 might not only prevent cell death by heterodimerizing with pro-apoptotic BAX or BAK proteins, subsequently abrogating the intrinsic mitochondrial pathway of apoptosis, but also by inducing a NF-κB-driven survival machinery. Using helenalin as tool we could confirm this notion. Helenalin is a known inhibitor of NF-κB [35] and although the inhibitory action of STLs on NF-κB is undisputed, their molecular mechanism of action remains a matter of debate.
Surface plasmon resonance analysis supported earlier reports that helenalin exerts a direct inhibitory effect on the activated p65 moiety rather than targeting IκB kinase β (IKKβ) [35, 49] . Importantly, next to helenalin the NF-κB inhibitor BMS is able to block
Bcl-2-mediated death resistance. This might open up a novel strategy to overcome
Bcl-2-induced chemoresistance at least in leukemic cells.
Interestingly, helenalin does not act as specific Bcl-2 inhibitor since neither typical mitochondrial activation features such as cytochrome c release, disruption of mitochondrial membrane potential and caspase activation nor classical apoptosis (phosphatidylserine translocation) could be seen in response to helenalin but are reported for specific Bcl-2 inhibitors such as the compound ABT-737 [7] . In contrast, helenalin is obviously able to bypass the survival mechanism of Bcl-2 at mitochondria. This is certainly a very important and promising feature with respect to chemoresistance that is frequently a consequence of deregulated apoptotic signalling.
Next to mitochondria, Bcl-2 may act also at the endoplasmic reticulum (ER)
influencing ER-stress-mediated cell death. The ER represents the most important storage site for Ca 2+ in the cell. Upon ER stress, high amounts of Ca 2+ can be released into the cytosol, mediating further downstream effects such as apoptosis [50] or autophagy [51] . We could not observe increased calcium level in response to helenalin treatment, although helenalin has been reported to decrease cellular glutathion levels [52] , which is frequently associated with an increase of resting intracellular calcium, leading to cytotoxicity [53] . Furthermore, helenalin does not alter the expression of BiP/GRP78 and CHOP/GADD153, two markers for ER-stress [54, 55] . Also distinct hallmarks of autophagy such as conversion of LC3 I to membranebound LC3 II were missing [27, 28] . Finally, the lack of phosphatidylserine translocation in helenalin-treated Bcl-2 overexpressing cells and the early onset of membrane permeability (PI positive staining) lead us to the assumption that helenalin induces cell death by necrosis. Necrosis often occurs when cell death programs such as apoptosis or autophagy are blocked [56] . Thus, necrosis is a mechanism that overcomes resistance to apoptosis as has been observed in a variety of human tumors [2] and in apoptosis-defective breast carcinomas treated with an anthracylinebased therapy [57] . There is now evidence that necrosis, traditionally considered an accidental form of cell death, can be initiated or modulated by programmed control mechanisms. ROS, calcium-ions, poly-ADP-ribose polymerase (PARP), calcium activated non-lysosomal proteases (calpains) and cathepsins are some of the mediators of necrosis [58] .
Recently two forms of programmed necrosis have been described: necroptosis and PARP1-mediated necrotic death [29] . Necroptosis is a form of programmed necrotic cell death under conditions where apoptosis is impeded [30] . Although induction of autophagy has been observed in a number of cell lines by necroptotic signaling, autophagy seems to be a downstream consequence of necroptosis rather than a contributing factor. RIP1 translocates to mitochondria causing disruption of the bonding of ANT with cyclophilin D leading to rapid mitochondrial dysfunction that is associated with necroptosis [29] . Necrostatins are well characterized inhibitors of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 M a n u s c r i p t 
